Chain of Custody in Regulated Bioanalysis: Protecting Every Sample, Every Record, Every Result

Chain of custody is also a data integrity issue

Chain of custody is often thought of as sample tracking. That is true, but in modern regulated bioanalysis, it is also about data integrity.

A sample moves through a physical and digital path. It may be received, registered, stored, prepared, extracted, amplified, sequenced, quantified, analyzed, reviewed, and reported. At each stage, the laboratory must preserve the link between the biological material and the data generated from it.

From an IT and data integrity perspective, this means records should be:

• attributable to the right person, instrument, or process,
• linked to the correct sample and study,
• protected from unauthorized change,
• available for review,
• supported by audit trails where applicable,
• retained according to defined requirements,
• and secure throughout storage and transfer.

This is in line with 21 CFR Part 11 and EU GMP Annex 11 requirements stating that audit trails shall be secure, computer-generated, and time-stamped, providing a complete and traceable history of record creation, modification, and deletion.

This is why the public TATAA services page highlights not only scientific technologies, but also high-level quality and IT controls such as a validated LIMS, robust QMS, backups for vital systems, regular audits, transparent communication, role-based access, e-signatures and IT security for data integrity and protection. The TATAA molecular technologies page repeats these public quality and compliance elements and lists qPCR, dPCR, NGS, and proteomics as molecular analysis technologies for precision bioanalysis.

In practical terms, chain of custody helps make sure that sample traceability and data traceability stay connected from receipt to result.

Chain of custody in cell and gene therapy bioanalysis

Cell and gene therapy studies often involve complex biological materials and highly sensitive molecular endpoints. TATAA publicly describes services for advanced therapies including gene therapies, RNA therapeutics, and RNA vaccines, with analysis of gene therapy analytes and biomarkers using qPCR, dPCR, NGS, and affinity-based proteomics.

In these programs, chain of custody supports confidence across services such as:

• biodistribution analysis,
• shedding,
• pharmacokinetics,
• pharmacodynamics,
• immune monitoring,
• vector copy number analysis,
• RCL/RCR testing.

For example, in biodistribution analysis, TATAA publicly describes GLP-accredited qPCR and dPCR assays for precise biodistribution analysis of gene therapy products, including AAV, CAR-T and cell therapy, mRNA, siRNA, miRNA, and ASO biodistribution.These studies depend on clear links between tissue or biofluid samples, storage conditions, analytical method, and final quantitative result.

In vector copy number analysis, TATAA publicly describes validated qPCR and dPCR assays for precise VCN analysis in engineered cell therapies and manufacturing support, with GLP/GCLP-aligned assay development and regulatory-ready data. Here, chain of custody helps ensure that cell material, DNA/RNA extracts, assay records, and reported copy number values remain traceable.

For sponsors, the value is simple: every result should have a documented path behind it.

Chain of custody in biodistribution, PK, and PD studies

In regulated advanced therapy development, biodistribution, pharmacokinetics, and pharmacodynamics are closely connected to sample traceability.

In biodistribution, samples may come from multiple tissues or biofluids and may be used to determine where a vector, RNA therapeutic, vaccine, or modified cell population is detected. TATAA publicly lists biodistribution samples including injection sites, gonads, adrenal gland, brain, spinal cord, liver, kidney, lung, heart, spleen, and blood.

In pharmacokinetics, TATAA publicly describes qPCR and dPCR assays for gene therapy and RNA therapeutics, including AAV pharmacokinetics, CAR-T pharmacokinetics, mRNA pharmacokinetics, and siRNA, miRNA and ASO pharmacokinetics.

In pharmacodynamics, TATAA publicly describes GLP-accredited and GCLP-compliant pharmacodynamic analyses for drug effects, including PD biomarker quantification, drug target engagement, vector functionality, transgene expression, CAR-T expansion, and immune activation.

For all these services, chain of custody supports a common goal: making sure the analytical result can be traced back to the correct sample, correct study context, and correct handling history.

Chain of custody in biomarker analysis

Biomarker studies depend on reliable links between samples, assays, and biological interpretation.

TATAA publicly describes biomarker discovery and validation services covering proteomic, transcriptomic, and genomic exploratory biomarker analysis for clinical and preclinical drug development. The same public page describes RNA biomarker discovery using transcriptome profiling, protein biomarker discovery using affinity-based proteomic biomarker panels, genomic biomarker discovery using NGS technologies, and biomarker qualification and validation using high-precision qPCR and dPCR methods.

This makes chain of custody important across the biomarker lifecycle:

• during sample receipt and identification,
• during RNA, DNA, or protein analysis,
• during data generation and QC,
• during bioinformatics or quantitative analysis,
• during reporting and retention.

For gene expression analysis, TATAA publicly describes GLP- and GCLP-compliant CRO services for assay development, validation, and high-throughput analysis using qPCR, dPCR, and RNA-Seq workflows.  For GCLP RNA-seq, the public page explicitly refers to full traceability and quality oversight, sample handling and chain of custody, audit trails from sample receipt to reporting, and regulatory-supportive data management following ALCOA+ principles.

That public GCLP RNA-seq language gives TATAA a strong, credible position: chain of custody is not a generic claim — it is visibly connected to traceability, audit trails, secure archiving, QMS documentation, and regulated transcriptomic data management.

Chain of custody and molecular technologies: qPCR, dPCR, NGS, and proteomics

Chain of custody must work across the technologies used to generate molecular data.

TATAA’s public molecular technologies page lists qPCR, dPCR, NGS, and proteomics as core molecular analysis technologies for precision bioanalysis.

For qPCR services, TATAA publicly describes GLP/GCLP qPCR services for drug development, including assay design, validation, and high-throughput analysis for gene therapy, RNA therapeutics bioanalysis, and biomarker gene expression analysis. The qPCR page also describes absolute qPCR for regulated assays such as copy number analysis of AAVs, biodistribution, shedding, pharmacokinetics, and transgene expression.

For NGS, TATAA publicly describes high-throughput DNA and RNA sequencing for genomic and transcriptomic analysis, including RNA-Seq, DNA-Seq, TCR-Seq, and BCR-Seq.

For proteomics, TATAA publicly describes Olink and Illumina Protein Prep services enabling high-plex protein analysis using affinity-based proteomics with only microliters of plasma or blood.

Across these platforms, the chain-of-custody expectation is the same: sample identity, analytical records, QC data, data files, and reports must remain connected.

What sponsors should expect from an audit-ready bioanalytical CRO

A sponsor choosing a regulated molecular bioanalysis CRO should look for more than technical capability. The laboratory should be able to explain — at a high level — how it protects sample traceability, data integrity, and audit readiness.

Useful questions include:

• Can samples be traced from receipt to report?
• Are sample identity, storage, processing, and disposition documented?
• Are data and records protected against unauthorized change?
• Are audit trails used where applicable?
• Are electronic records retained securely?
• Are GLP or GCLP expectations supported when required?
• Are deviations or discrepancies documented and communicated?
• Are quality systems and review processes in place?

DAIDS GCLP guidance states that laboratories should maintain a complete audit trail for every specimen from collection to disposal or storage, including date/time and personnel responsible for activities, and that chain-of-custody documentation should include information such as collection site, specimen type, receiver identity, date and time of receipt, observed sample condition, and other factors affecting specimen integrity. The same guidance describes laboratory information system expectations around audit trails, access/security, system validation, backup procedures, restoration, and protection of participant confidentiality.

This is why chain of custody belongs in both the quality conversation and the IT conversation.

TATAA’s position: traceability as part of scientific confidence

TATAA Biocenter is strongly positioned in chain of custody because its public messaging already connects advanced molecular science with regulated quality infrastructure.

The services page publicly describes TATAA as a leading CRO specializing in bioanalysis for ASOs, CRISPR, siRNA, mRNA, and other advanced modalities, and states that TATAA accelerates drug development with expertise, experience, and a market-leading compliant laboratory. The same page publicly highlights GLP and GCLP compliance, a validated LIMS, robust QMS, backups for vital systems, regular audits, transparent communication, IT security for data integrity and protection, and market-leading qPCR, dPCR, and NGS platforms. In addition, GDPR and data privacy are critical in a CRO setting to ensure the lawful, secure, and confidential handling of personal and clinical research data, protecting study participants while maintaining regulatory compliance and sponsor trust.

That combination matters.

A strong chain of custody is not created by one document or one system. It comes from the alignment of people, process, technology, quality management, secure records, and scientific expertise. It ensures that samples are not only analyzed correctly, but also documented, protected, and connected to reliable results.

For sponsors developing advanced therapies and biomarkers, that traceability is a strategic advantage.